CytomX Therapeutics Announces New Employment Inducement Grants
CytomX Therapeutics Announces New Employment Inducement Grants
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript
Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Gold Moves Higher; Roblox Issues Weak Outlook
CCLD, SKYT and SEED among mid-day movers
Dow Jumps Over 150 Points; US Foods Posts Upbeat Earnings
CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic Partnerships and Promising Pipeline Progress
Q1 2024 CytomX Therapeutics Inc Earnings Call Transcript
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
CytomX GAAP EPS of $0.17 beats by $0.24, revenue of $41.46M beats by $19.74M
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Owens & Minor (OMI), Idexx Laboratories (IDXX) and CytomX Therapeutics (CTMX)
Buy Rating for CytomX Therapeutics on Promising CX-904 Probody Therapy Prospects
CTMX, HSDT and SNSE are among premarket gainers
Etsy Reports Downbeat Earnings, Joins Fastly, DoorDash And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.